Browse News
Filter News
Found 49 articles
-
For the first time in two years, the European Association for the Study of the Liver’s International Liver Congress was back on-site with cutting-edge research in hepatology and other sectors.
-
Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study
6/25/2022
Antios Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for hepatitis B virus, announced new data from the Phase 2a clinical trial of ATI-2173, its lead investigational proprietary drug candidate and the only Active Site Polymerase Inhibitor Nucleotide in clinical development for HBV.
-
Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress™ 2022
6/8/2022
Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to advance treatments that can provide a bridge to a cure for chronic hepatitis B virus (HBV), today announced the acceptance of oral presentations highlighting ATI-2173, Antios' lead therapeutic HBV candidate .
-
Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday.
-
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
5/12/2022
Assembly Biosciences, Inc. reported financial results and recent highlights for the first quarter ended March 31, 2022.
-
Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus
4/26/2022
Antios Therapeutics, Inc today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/312,756.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies
3/30/2022
Antios Therapeutics, Inc. today announced new data from the Phase 1b and 2a clinical trials of ATI-2173, its investigational proprietary drug candidate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development for HBV.
-
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
3/10/2022
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases, reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.
-
Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
3/3/2022
Arbutus Biopharma Corporation today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.
-
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
1/24/2022
Arbutus Biopharma Corporation today announced its 2022 corporate objectives and provided a financial update.
-
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
1/4/2022
Assembly Biosciences, Inc. today outlined anticipated progress and milestones for its development pipeline in 2022.
-
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
12/14/2021
Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection.
-
Antios Therapeutics Announces Presentations on ATI-2173 at Hep DART 2021 Meeting
12/6/2021
Antios Therapeutics, Inc. today announced two oral presentations will be presented at the Hep DART 2021 meeting being held December 5-9, 2021, in Cabo San Lucas, Mexico.
-
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
11/15/2021
Antios Therapeutics, Inc. announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV.
-
Money on the Move: November 3 – 9
11/10/2021
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here's who snagged funding this week. -
The proceeds will be used to advance the development of their ePLC platform, treatment for chronic Hepatitis B, and a novel class of anti-cancer therapies.
-
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/4/2021
Arbutus Biopharma Corporation today reports its third quarter 2021 financial results and provides a corporate update.
-
Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
11/4/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, reported financial results and recent highlights for the third quarter ended September 30, 2021.
-
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
11/3/2021
Antios Therapeutics, Inc. today announced the successful closing of a $75 million Series B-1 financing.